Cooloongup

Researchers are evaluating the effectiveness and safety of combining sonrotoclax with either obinutuzumab or rituximab compared to venetoclax plus rituximab in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma CLLSLL. This Phase 3 randomized study aims to understand which combination offers better progression-free survival and treatment outcomes in patients who have undergone prior therapies. The study has four treatment groups sonrotoclax combined with obinutuzumab, sonrotoclax combined with rituximab, sonrotoclax plus obinutuzumab with treatment guided by minimal residual disease evaluation, and venetoclax combined with rituximab. Sonrotoclax and venetoclax are given orally, while obinutuzumab and rituximab are administered intravenously. Participants receive these treatments according to their assigned group as part of this clinical research. Participants will be monitored for progression-free survival, overall survival, response rates, and minimal residual disease status over several months up to several years. Safety assessments include tracking treatment-emergent adverse events. Quality of life and symptom burden will be evaluated using questionnaires. The study involves regular visits for treatment administration and assessments, with follow-up extending up to 84 months to observe long-term outcomes.

Researchers are evaluating the combination of sonrotoclax plus zanubrutinib compared with zanubrutinib plus placebo in adults with relapsed or refractory mantle cell lymphoma MCL. This Phase 3 randomized, double-blind study aims to compare how well these treatments work and assess their safety in this patient population. The study is sponsored by BeOne Medicines and focuses on patients who have previously received 1 to 5 prior systemic therapies including anti-CD20 monoclonal antibody or chemoimmunotherapy. Participants will receive either sonrotoclax plus zanubrutinib or placebo plus zanubrutinib, both administered orally. The study has two groups one receiving the combination of sonrotoclax and zanubrutinib, and the other receiving zanubrutinib with placebo. Treatment continues as per protocol, and the study includes detailed assessments of response and safety over time. During the study, participants will be monitored for progression-free survival as the primary outcome, assessed by an independent review committee over approximately 41 months. Secondary outcomes include overall survival, response rates, duration of response, health-related quality of life, and adverse events up to around 58 months. Regular evaluations will be conducted to assess disease status, quality of life, and safety throughout the trial, which is planned to complete by 2032.

Researchers are evaluating the safety of new dosing and ramp-up schedules for sonrotoclax in adults with blood cancers, including chronic lymphocytic leukemia CLL and mantle cell lymphoma MCL. This study aims to focus on tumor lysis syndrome TLS and related toxicities caused by the drug. Sonrotoclax works by blocking a protein called BCL-2, which helps slow or stop tumor growth and promote tumor cell death. Zanubrutinib, another drug blocking Brutons tyrosine kinase BTK, is also included and is approved for treating these B-cell malignancies worldwide. Participants will first receive zanubrutinib alone, followed by a combination with sonrotoclax using a gradual dose ramp-up based on specific schedules defined in the study protocol. Treatment lasts 15 cycles of 28 days for treatment-naefve CLL participants or 27 cycles for relapsedrefractory MCL participants, with some continuing zanubrutinib alone afterward. The study takes place at multiple centers worldwide and aims to optimize the ramp-up schedule to potentially benefit patients and caregivers. Participants will be monitored for safety during treatment, focusing on the occurrence of tumor lysis syndrome within approximately four months. Adverse events and dose modifications will also be recorded during this period. The total participation duration is about 17 months for treatment-naefve CLL and about 32 months for relapsedrefractory MCL participants, including treatment and follow-up assessments.